Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.69M 16.39M 15.11M 14.14M 26.5M 1.76B 27.07M 70.29M 869M 70.18M 68.64M 3.04B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 40.67M 35.68M 32.89M 30.78M 57.68M 3.84B 58.91M 153M 1.89B 153M 149M 6.62B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

IRRAS AB (publ) Stock London S.E.

Stocks

0GDW

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB (publ)

Latest news : IRRAS AB (publ)

Analysts' recommendations: IRRAS AB (publ)

Press Releases: IRRAS AB (publ)

Quotes and Performance

Managers and Directors: IRRAS AB (publ)

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB (PUBL)	-3.63%	-70.75%	-	-	16.9M
STRYKER CORPORATION	+5.25%	+8.09%	-15.17%	+11.69%	121B
SMITH & NEPHEW PLC	-0.65%	+0.53%	+3.83%	-7.89%	12.85B
GLAUKOS CORPORATION	+1.30%	+10.51%	+45.42%	+114.05%	8.37B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-3.88%	-6.41%	-50.89%	-72.88%	3.95B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.38%	-0.97%	+16.76%	+37.20%	2.53B
L&C BIO CO.,LTD	-9.06%	+10.10%	+218.77%	+159.71%	1.7B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.75%	-13.25%	-27.64%	-24.60%	1.68B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-2.80%	-3.48%	-2.92%	-23.20%	1.57B
Average	-2.51%	-0.90%	+23.52%	+24.26%	19.23B
Weighted average by Cap.	+3.82%	+2.40%	-8.11%	+14.76%

	2023	2024
Net sales	42.88M 4.41M 3.87M 3.57M 3.34M 6.25M 416M 6.39M 16.58M 205M 16.56M 16.19M 718M	57.98M 5.96M 5.23M 4.82M 4.51M 8.46M 562M 8.64M 22.43M 277M 22.39M 21.9M 971M
Net income	-209M -21.48M -18.84M -17.37M -16.25M -30.46M -2.03B -31.11M -80.79M -999M -80.65M -78.88M -3.5B	-95.98M -9.87M -8.66M -7.98M -7.47M -14M -931M -14.29M -37.12M -459M -37.06M -36.25M -1.61B
Net Debt	43.85M 4.51M 3.96M 3.65M 3.41M 6.39M 425M 6.53M 16.96M 210M 16.93M 16.56M 734M	214M 21.98M 19.28M 17.78M 16.64M 31.17M 2.07B 31.84M 82.69M 1.02B 82.55M 80.74M 3.58B